(INVE-B) Investor ser. - Ratings and Ratios
Private Equity, Financial Services, Health Care, Technology Investments
INVE-B EPS (Earnings per Share)
INVE-B Revenue
Description: INVE-B Investor ser.
Investor AB (publ) is a private equity firm that specializes in mature, middle-market buyouts and growth capital investments, focusing on healthcare, financial services, IT, and fintech sectors. The firm invests globally, with a preference for medium-sized to large companies headquartered in Northern Europe.
Key investment strategies include taking majority or minority positions in both listed and unlisted companies, with a typical investment range of SEK 20 million to SEK 200 million. The firm aims to exit private equity investments within three to seven years and often takes board membership in portfolio companies.
From a financial perspective, Investor AB has a market capitalization of approximately SEK 863.88 billion. The companys return on equity (ROE) is 5.22%, indicating a relatively modest return on shareholders equity. The price-to-earnings (P/E) ratio is 19.96, suggesting that the stock is fairly valued relative to its earnings. To further evaluate the companys performance, additional KPIs such as dividend yield, debt-to-equity ratio, and net asset value (NAV) per share could be considered.
To assess the attractiveness of Investor AB as an investment opportunity, it is essential to analyze its historical financial performance, portfolio composition, and growth prospects. Some key metrics to examine include the companys NAV growth, investment income, and operating expenses. Additionally, evaluating the firms investment pipeline, deal flow, and exit strategy can provide insights into its potential for future growth.
INVE-B Stock Overview
| Market Cap in USD | 93,646m |
| Sub-Industry | Environmental & Facilities Services |
| IPO / Inception |
INVE-B Stock Ratings
| Growth Rating | 36.2% |
| Fundamental | 45.5% |
| Dividend Rating | 58.3% |
| Return 12m vs S&P 500 | -16.3% |
| Analyst Rating | - |
INVE-B Dividends
| Dividend Yield 12m | 2.18% |
| Yield on Cost 5y | 5.09% |
| Annual Growth 5y | 16.36% |
| Payout Consistency | 91.6% |
| Payout Ratio | 65.0% |
INVE-B Growth Ratios
| Growth Correlation 3m | 77.4% |
| Growth Correlation 12m | -50.3% |
| Growth Correlation 5y | 90.1% |
| CAGR 5y | 18.50% |
| CAGR/Max DD 5y | 0.61 |
| Sharpe Ratio 12m | 0.50 |
| Alpha | -15.61 |
| Beta | 0.745 |
| Volatility | 15.97% |
| Current Volume | 1783.2k |
| Average Volume 20d | 1779.3k |
| Stop Loss | 284.5 (-3%) |
| Signal | -1.42 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (23.36b TTM) > 0 and > 6% of Revenue (6% = 4.89b TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -0.04pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 60.37% (prev 24.26%; Δ 36.11pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.02 (>3.0%) and CFO 24.28b > Net Income 23.36b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 9.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (3.06b) change vs 12m ago -0.03% (target <= -2.0% for YES) |
| Gross Margin 72.67% (prev 71.86%; Δ 0.81pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 8.35% (prev 12.26%; Δ -3.91pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.63 (EBITDA TTM -16.95b / Interest Expense TTM 6.80b) >= 6 (WARN >= 3) |
Altman Z'' 2.83
| (A) 0.05 = (Total Current Assets 54.93b - Total Current Liabilities 5.74b) / Total Assets 985.32b |
| (B) 0.79 = Retained Earnings (Balance) 782.84b / Total Assets 985.32b |
| (C) -0.02 = EBIT TTM -17.89b / Avg Total Assets 975.27b |
| (D) 0.03 = Book Value of Equity 4.79b / Total Liabilities 145.01b |
| Total Rating: 2.83 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 45.45
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield 1.96% = 0.98 |
| 3. FCF Margin 24.15% = 6.04 |
| 4. Debt/Equity 0.18 = 2.48 |
| 5. Debt/Ebitda -8.81 = -2.50 |
| 6. ROIC - WACC -9.65% = -12.06 |
| 7. RoE 2.82% = 0.23 |
| 8. Rev. Trend -30.94% = -1.55 |
| 9. Rev. CAGR 49.30% = 2.50 |
| 10. EPS Trend -27.26% = -0.68 |
| 11. EPS CAGR 84.81% = 2.50 |
What is the price of INVE-B shares?
Over the past week, the price has changed by -0.09%, over one month by +0.84%, over three months by +4.10% and over the past year by -1.47%.
Is Investor ser. a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of INVE-B is around 306.61 SEK . This means that INVE-B is currently overvalued and has a potential downside of 4.5%.
Is INVE-B a buy, sell or hold?
What are the forecasts/targets for the INVE-B price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 313.8 | 6.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 339.5 | 15.7% |
INVE-B Fundamental Data Overview
Market Cap SEK = 891.87b (891.87b SEK * 1.0 SEK.SEK)
CCE Cash And Equivalents = 37.47b SEK (Cash And Short Term Investments, last quarter)
P/E Trailing = 38.2218
P/S = 10.4718
P/B = 1.0561
Beta = 0.772
Revenue TTM = 81.47b SEK
EBIT TTM = -17.89b SEK
EBITDA TTM = -16.95b SEK
Long Term Debt = 145.01b SEK (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 4.43b SEK (from shortTermDebt, last fiscal year)
Debt = 149.45b SEK (Calculated: Short Term 4.43b + Long Term 145.01b)
Net Debt = 72.71b SEK (from netDebt column, last quarter)
Enterprise Value = 1003.85b SEK (891.87b + Debt 149.45b - CCE 37.47b)
Interest Coverage Ratio = -2.63 (Ebit TTM -17.89b / Interest Expense TTM 6.80b)
FCF Yield = 1.96% (FCF TTM 19.68b / Enterprise Value 1003.85b)
FCF Margin = 24.15% (FCF TTM 19.68b / Revenue TTM 81.47b)
Net Margin = 28.68% (Net Income TTM 23.36b / Revenue TTM 81.47b)
Gross Margin = 72.67% ((Revenue TTM 81.47b - Cost of Revenue TTM 22.27b) / Revenue TTM)
Tobins Q-Ratio = 209.4 (set to none) (Enterprise Value 1003.85b / Book Value Of Equity 4.79b)
Interest Expense / Debt = 1.56% (Interest Expense 2.33b / Debt 149.45b)
Taxrate = 1.06% (from yearly Income Tax Expense: 1.22b / 114.39b)
NOPAT = -17.89b (EBIT -17.89b, no tax applied on loss)
Current Ratio = 9.56 (Total Current Assets 54.93b / Total Current Liabilities 5.74b)
Debt / Equity = 0.18 (Debt 149.45b / last Quarter total Stockholder Equity 839.99b)
Debt / EBITDA = -8.81 (Net Debt 72.71b / EBITDA -16.95b)
Debt / FCF = 7.59 (Debt 149.45b / FCF TTM 19.68b)
Total Stockholder Equity = 829.45b (last 4 quarters mean)
RoA = 2.37% (Net Income 23.36b, Total Assets 985.32b )
RoE = 2.82% (Net Income TTM 23.36b / Total Stockholder Equity 829.45b)
RoCE = -1.84% (Ebit -17.89b / (Equity 829.45b + L.T.Debt 145.01b))
RoIC = -1.92% (NOPAT -17.89b / Invested Capital 931.46b)
WACC = 7.72% (E(891.87b)/V(1041.32b) * Re(8.76%)) + (D(149.45b)/V(1041.32b) * Rd(1.56%) * (1-Tc(0.01)))
Shares Correlation 5-Years: -20.0 | Cagr: 0.01%
Discount Rate = 8.76% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 67.28% ; FCFE base≈19.68b ; Y1≈12.92b ; Y5≈5.91b
Fair Price DCF = 56.83 (DCF Value 103.21b / Shares Outstanding 1.82b; 5y FCF grow -40.0% → 3.0% )
Revenue Correlation: -30.94 | Revenue CAGR: 49.30%
Rev Growth-of-Growth: 57.37
EPS Correlation: -27.26 | EPS CAGR: 84.81%
EPS Growth-of-Growth: -27.09